Supplemental material
OncoImmunology
Volume 13, 2024 - Issue 1
Open access
719
Views
0
CrossRef citations to date
0
Altmetric
Original Research
Peripheral CX3CR1+ T cells combined with PD-1 blockade therapy potentiates the anti-tumor efficacy for lung cancer
Congcong Lia Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Zhen Zhanga Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;b State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Qianfeng Caia Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;c School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Qitai Zhaoa Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Han Wua Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, JunRu Lia Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Yaqing Liua Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Xuan Zhaoa Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Jinyan Liua Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Yu Pinga Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Jiqi Shana Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaView further author information
, Shengli Yanga Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaCorrespondence[email protected]
View further author information
& View further author information
Yi Zhanga Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;b State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, China;c School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China;d Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan, ChinaCorrespondence[email protected]
https://orcid.org/0000-0001-9861-4681View further author information
Article: 2355684
|
Received 16 Jan 2024, Accepted 11 May 2024, Published online: 22 May 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.